Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci otrzymujący chemioterapię paclitaxelem i carboplatyną z powodu raka ginekologicznego
- •Brak wcześniejszych alergicznych reakcji na paclitaxel lub carboplatin
- •Zdolność do przeczytania informacji i podpisania świadomej zgody
- •Wiek 19 lat lub więcej
✗ Disqualifies
- •Niepełna dobrowolność uczestniczenia w badaniu
- •Osoby uznane przez lekarza za niestosowne do udziału w tym badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- October 7, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Seoul National University Hospital
Seoul, South Korea
Trial contact
Hye-Ryun Kang, MD, PhD
Jiyeon Park, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.